Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2017 | Pages:
167 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Attention Deficit Hyperactivity Disorder - Pipeline Review, H1 2017, provides an overview of the Attention Deficit Hyperactivity Disorder (Central Nervous System) pipeline landscape. Attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness. Symptoms of ADHD include disorganized work habits, procrastination and inability to sustain attention on tasks or activities. Treatment includes analeptics. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Attention Deficit Hyperactivity Disorder - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Attention Deficit Hyperactivity Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Attention Deficit Hyperactivity Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 6, 11, 8, 15, 6 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 2 molecules, respectively. Attention Deficit Hyperactivity Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Attention Deficit Hyperactivity Disorder (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Attention Deficit Hyperactivity Disorder (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Attention Deficit Hyperactivity Disorder (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Attention Deficit Hyperactivity Disorder (Central Nervous System) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Attention Deficit Hyperactivity Disorder (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Attention Deficit Hyperactivity Disorder (ADHD) - Overview 8 Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics Development 9 Pipeline Overview 9 Pipeline by Companies 10 Pipeline by Universities/Institutes 14 Products under Development by Companies 15 Products under Development by Universities/Institutes 18 Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics Assessment 19 Assessment by Target 19 Assessment by Mechanism of Action 22 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Attention Deficit Hyperactivity Disorder (ADHD) - Companies Involved in Therapeutics Development 29 Aevi Genomic Medicine Inc 29 Alcobra Ltd 29 Amarantus Bioscience Holdings Inc 30 APeT Holding BV 30 Arbor Pharmaceuticals LLC 31 BCWorld Pharm Co Ltd 31 BioHealthonomics Inc 32 BioLite Inc 32 Cingulate Therapeutics LLC 33 Collegium Pharmaceutical Inc 33 Curemark LLC 34 DURECT Corp 34 Eli Lilly and Company 35 Ensysce Biosciences Inc 35 H. Lundbeck A/S 36 Heptares Therapeutics Ltd 36 Highland Therapeutics Inc 37 Integrative Research Laboratories Sweden AB 37 INVENT Pharmaceuticals Inc 38 KemPharm Inc 38 Luc Therapeutics Inc 39 Merck & Co Inc 39 Neos Therapeutics Inc 40 NeuroDerm Ltd 40 Neurovance Inc 41 NLS Pharma Group 41 Noven Pharmaceuticals Inc 42 P2D Bioscience 42 Reviva Pharmaceuticals Inc 43 Shire Plc 43 SK Biopharmaceuticals Co Ltd 44 Sunovion Pharmaceuticals Inc 44 Supernus Pharmaceuticals Inc 45 Taisho Pharmaceutical Co Ltd 45 TRImaran Pharma Inc 46 Attention Deficit Hyperactivity Disorder (ADHD) - Drug Profiles 47 (nicotine + opipramol hydrochloride) - Drug Profile 47 4-P003 - Drug Profile 48 AR-08 - Drug Profile 49 BCWPE-003 - Drug Profile 50 BLI-1008 - Drug Profile 51 BNC-375 - Drug Profile 52 CB-8411 - Drug Profile 54 centanafadine SR - Drug Profile 55 CM-4612 - Drug Profile 58 CTX-1301 - Drug Profile 59 CTX-1302 - Drug Profile 60 dasotraline hydrochloride - Drug Profile 61 dextroamphetamine - Drug Profile 64 dextroamphetamine IR - Drug Profile 65 dextroamphetamine MR - Drug Profile 66 edivoxetine hydrochloride - Drug Profile 68 eltoprazine - Drug Profile 70 fasoracetam - Drug Profile 75 guanfacine hydrochloride ER - Drug Profile 77 histamine dihydrochloride - Drug Profile 79 HTL-1071 - Drug Profile 80 INV-107 - Drug Profile 82 IRL-752 - Drug Profile 83 KP-415 CR - Drug Profile 84 levofacetoperane - Drug Profile 86 lisdexamfetamine dimesylate - Drug Profile 87 mazindol - Drug Profile 94 methylphenidate hydrochloride ER - Drug Profile 96 methylphenidate hydrochloride MR - Drug Profile 97 methylphenidate hydrochloride SR - Drug Profile 102 methylphenidate hydrochloride XR - Drug Profile 104 modafinil - Drug Profile 107 molindone hydrochloride ER - Drug Profile 108 niacinamide CR - Drug Profile 110 NLS-4 - Drug Profile 111 NLS-8 - Drug Profile 112 NT-0201 - Drug Profile 113 P-001 - Drug Profile 114 PBF-509 - Drug Profile 115 PD-2005 - Drug Profile 116 PD-3044 - Drug Profile 117 PFR-08001 - Drug Profile 118 PFR-8026 - Drug Profile 119 RP-5063 - Drug Profile 120 SHP-465 - Drug Profile 123 SKL-ADHD - Drug Profile 125 Small Molecule to Block Dopamine, Norepinephrine and Serotonin Transporter for Attention Deficit Hyperactivity Disorder - Drug Profile 126 Small Molecules to Activate High Affinity Choline Transporter for Attention Deficit Hyperactivity Disorder - Drug Profile 127 Small Molecules to Agonize NMDA2D for Attention Deficit Hyperactivity Disorder - Drug Profile 128 Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile 129 Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile 130 Small Molecules to Inhibit Sodium Hydrogen Exchanger for ADHD - Drug Profile 131 Synthetic Peptide to Antagonize D2 for ADHD - Drug Profile 132 TS-141 - Drug Profile 133 Vaccine for CNS Disorders - Drug Profile 134 viloxazine hydrochloride ER - Drug Profile 135 vortioxetine hydrobromide - Drug Profile 137 VU-0238429 - Drug Profile 143 Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects 144 Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products 149 Attention Deficit Hyperactivity Disorder (ADHD) - Product Development Milestones 150 Featured News & Press Releases 150 Appendix 162 Methodology 162 Coverage 162 Secondary Research 162 Primary Research 162 Expert Panel Validation 162 Contact Us 162 Disclaimer 163
List of Tables
Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Aevi Genomic Medicine Inc, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Alcobra Ltd, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by APeT Holding BV, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Arbor Pharmaceuticals LLC, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BCWorld Pharm Co Ltd, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BioHealthonomics Inc, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BioLite Inc, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Cingulate Therapeutics LLC, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Collegium Pharmaceutical Inc, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Curemark LLC, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by DURECT Corp, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Eli Lilly and Company, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Ensysce Biosciences Inc, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by H. Lundbeck A/S, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Heptares Therapeutics Ltd, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Highland Therapeutics Inc, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Integrative Research Laboratories Sweden AB, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by INVENT Pharmaceuticals Inc, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by KemPharm Inc, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Luc Therapeutics Inc, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Merck & Co Inc, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Neos Therapeutics Inc, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by NeuroDerm Ltd, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Neurovance Inc, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by NLS Pharma Group, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Noven Pharmaceuticals Inc, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by P2D Bioscience, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Reviva Pharmaceuticals Inc, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Shire Plc, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Sunovion Pharmaceuticals Inc, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Supernus Pharmaceuticals Inc, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Taisho Pharmaceutical Co Ltd, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by TRImaran Pharma Inc, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H1 2017 (Contd..1), H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H1 2017 (Contd..2), H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H1 2017 (Contd..3), H1 2017 Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
